Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a ra...
Charles River Laboratories International (NYSE:CRL) has partnered with MEDIPOST to expand its cell therapy development and commercialization services ...
Bullish
Charles River Laboratories and MEDIPOST Co., Ltd. have signed a non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testin...
Neutral
Charles River Laboratories International Inc (CRL) saw its stock fall by 5.2% to $168.46 on May 12, 2026. According to GuruFocus, the stock is conside...
Charles River Laboratories International (CRL) has seen recent share price momentum, placing its stock near US$181. Valuation analyses offer conflicti...
Charles River Laboratories International, Inc. (CRL) announced its Q1 revenue reached $995.8 million, surpassing FactSet's estimate of $977.5 million....
Charles River Laboratories reported its Q1 2026 results, showing a GAAP loss per share of $(0.30) despite revenue of $995.8 million, primarily due to ...